Trial Profile

A Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NTRX-07 in Subjects With Mild Cognitive Impairment or Mild to Moderate Alzheimer's Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Jul 2025 Status changed from planning to recruiting.
04 Feb 2025 According to a NeuroTherapia media release, trial will be managed by CRU Global, a leading European CRO, and conducted at sites in Hungary, Poland, and the Czech Republic. Sites are currently completing training for administrating qEEG and P300 ERP recordings, with patient enrollment expected to begin in February.
04 Feb 2025 According to a NeuroTherapia media release, company announced it has received approval for its Phase 2 clinical trial from the European Medicines Agency (EMA).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com